Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Clinical Studies on the Therapeutic Value of Adult Human Stem Cells

Clinical Studies on the Therapeutic Value of Adult Human Stem Cells

Tuesday, September 25, 2007

Lighthouse International Conference Center

Presented By

Presented by the Biochemical Pharmacology Discussion Group and the American Chemical Society's New York Section


Organizers: Keith Haskell, Pfizer Global R & D and John Hambor, Cognate Bioservices

Adult stem cells possess properties of self-renewal and pluripotency, where they play a role in homeostatic tissue regeneration, as well as the repair of injured or diseased tissue. An accepted modality, adult stem cells have been used either exclusively or in combination with other treatments to achieve significant healthcare benefits for sufferers of multiple conditions. Furthermore, the future application of adult stem cells for treatment therapies, where clinical trials have already indicated significant potential benefit, include Parkinson's, Alzheimer's, spinal cord injuries, organ transplantation, blood production, muscle regeneration, diabetes, and heart disease. This symposium will focus on recent ground breaking medical research using stem cells where it has become clear that adult stem cells have outstanding advantages in terms of immediate clinical application, safety and feasibility over all other sources of stem cells.


8:30 - 9:00 AM: Registration and Refreshments

9:00 - 9:10 AM: Welcoming Remarks

9:10 - 9:50 AM:
Richard Burt, Northwestern University
Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

9:50 - 10:30 AM:
Michael Haller, University of Florida
Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes

10:30 - 10:50 AM: Coffee Break

10:50 - 11:30 AM:
Pablo Rubinstein, New York Blood Center
Umbilical Cord Blood Banking and Transplantation for Adults

11:30 - 12:10 PM:
Mary Laughlin,
Case Western Reserve University
Influence of HLA Disparity and Graft Lymphocytes on Allogeneic Engraftment and Survival after UCB Transplant in Adults

12:10 - 1:15 PM: Lunch

1:15 - 1:55 PM:
Robert Steiner,
Oregon Health and Science University
A Phase 1 Clinical Study of Human CNS Stem Cells (HUCNS-SC) in Neuronal Ceroid Lipofuscinosis

1:55 - 2:35 PM:
Suzanne Ildstad,
University of Louisville
The Promise of Facilitating Stem Cell Mediated Reversal of Diabetes and Promoting Islet Neogenesis

2:35 - 3:15 PM:
Adam Katz
, University of Virginia
Adipose Stem Cells for Wound Healing: The Therapeutic Impact of Cell Preparation and Delivery

3:15 - 3:35 PM: Coffee Break

3:35 - 4:15 PM:
Timothy Henry,
Minneapolis Heart Institute Foundation
CD34+ Stem Cells for Refractory Ischemia

4:15 - 4:55 PM:
William Fodor
, Viacell Inc.
The Use of Umbilical Cord Blood Stem Cells to Treat Acute Myocardial Infarction

4:55 - 5:00 PM: Closing Remarks


Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes
Michael Haller,
University of Florida

The long term morbidity and mortality associated with type 1 diabetes requires the continued investigation of safe and effective interventions for reversal of the disease. As the use of stem cells in non-traditional treatment arenas has continued to emerge as a potential therapy for many diseases we ventured to explore the potential of autologous cord blood infusion as a source of immunotherapy in children with type 1 diabetes. Preliminary data suggest potential benefit and imply the mechanism may be related to increases in regulatory T